Bain Capital Life Sciences Fund Ii, L.p. - Net Worth and Insider Trading
Bain Capital Life Sciences Fund Ii, L.p. Net Worth
The estimated net worth of Bain Capital Life Sciences Fund Ii, L.p. is at least $3 Million dollars as of 2024-05-28. Bain Capital Life Sciences Fund Ii, L.p. is the 10% Owner of Xilio Therapeutics Inc and owns about 2,805,413 shares of Xilio Therapeutics Inc (XLO) stock worth over $3 Million. Details can be seen in Bain Capital Life Sciences Fund Ii, L.p.'s Latest Holdings Summary section.
Disclaimer: The insider information is derived from SEC filings. The estimated net worth is based on the assumption that Bain Capital Life Sciences Fund Ii, L.p. has not made any transactions after 2021-12-10 and currently still holds the listed stock(s).
Transaction Summary of Bain Capital Life Sciences Fund Ii, L.p.
Bain Capital Life Sciences Fund Ii, L.p. Insider Ownership Reports
Based on ownership reports from SEC filings, as the reporting owner, Bain Capital Life Sciences Fund Ii, L.p. owns 2 companies in total, including Xilio Therapeutics Inc (XLO) , and Solid Biosciences Inc (SLDB) .
Insider Ownership Summary of Bain Capital Life Sciences Fund Ii, L.p.
| Ticker | Comapny | Transaction Date | Type of Owner |
|---|---|---|---|
| XLO | Xilio Therapeutics Inc | 2021-12-10 | 10 percent owner |
| SLDB | Solid Biosciences Inc | 2022-12-02 | 10 percent owner |
Bain Capital Life Sciences Fund Ii, L.p. Latest Holdings Summary
Bain Capital Life Sciences Fund Ii, L.p. currently owns a total of 1 stock. Bain Capital Life Sciences Fund Ii, L.p. owns 2,805,413 shares of Xilio Therapeutics Inc (XLO) as of December 10, 2021, with a value of $3 Million.
Latest Holdings of Bain Capital Life Sciences Fund Ii, L.p.
| Ticker | Comapny | Latest Transaction Date | Shares Owned | Current Price ($) | Current Value ($) |
|---|---|---|---|---|---|
| XLO | Xilio Therapeutics Inc | 2021-12-10 | 2,805,413 | 1.05 | 2,945,684 |
Holding Weightings of Bain Capital Life Sciences Fund Ii, L.p.
Bain Capital Life Sciences Fund Ii, L.p. Form 4 Trading Tracker
According to the SEC Form 4 filings, Bain Capital Life Sciences Fund Ii, L.p. has made a total of 1 transactions in Xilio Therapeutics Inc (XLO) over the past 5 years, including 1 buys and 0 sells. The most-recent trade in Xilio Therapeutics Inc is the acquisition of 42,469 shares on December 10, 2021, which cost Bain Capital Life Sciences Fund Ii, L.p. around $410,251.
Insider Trading History of Bain Capital Life Sciences Fund Ii, L.p.
- 1
Bain Capital Life Sciences Fund Ii, L.p. Trading Performance
GuruFocus tracks the stock performance after each of Bain Capital Life Sciences Fund Ii, L.p.'s buying transactions within different timeframes. To be detailed, the average return of stocks after 3 months bought by Bain Capital Life Sciences Fund Ii, L.p. is -24.1%. GuruFocus also compares Bain Capital Life Sciences Fund Ii, L.p.'s trading performance to market benchmark return within the same time period. The performance of stocks bought by Bain Capital Life Sciences Fund Ii, L.p. within 3 months outperforms 0 times out of 1 transactions in total compared to the return of S&P 500 within the same period.
You can select different timeframes to see how Bain Capital Life Sciences Fund Ii, L.p.'s insider trading performs compared to the benchmark.
Performance of Bain Capital Life Sciences Fund Ii, L.p.
Average Return
Outperforming Transactions
| 1 Month | 3 Months | 6 Months | 1 Year | 2 Years | 3 Years | |
|---|---|---|---|---|---|---|
| Return(%) | 44.39 | | | | | |
| Relative Return to S&P 500(%) | 45.28 | | | | | |
Bain Capital Life Sciences Fund Ii, L.p. Ownership Network
Bain Capital Life Sciences Fund Ii, L.p. Owned Company Details
What does Xilio Therapeutics Inc do?
Who are the key executives at Xilio Therapeutics Inc?
Bain Capital Life Sciences Fund Ii, L.p. is the 10 percent owner of Xilio Therapeutics Inc. Other key executives at Xilio Therapeutics Inc include 10 percent owner Atlas Venture Fund Xi, L.p. , Chief Medical Officer Katarina Luptakova , and Chief Operating Officer Christopher James Frankenfield .
Xilio Therapeutics Inc (XLO) Insider Trades Summary
Over the past 18 months, Bain Capital Life Sciences Fund Ii, L.p. made no insider transaction in Xilio Therapeutics Inc (XLO). Other recent insider transactions involving Xilio Therapeutics Inc (XLO) include a net sale of 5,235 shares made by Atlas Venture Fund Xi, L.p. , and a net purchase of 485,250 shares made by Gilead Sciences Inc .
In summary, during the past 3 months, insiders sold 0 shares of Xilio Therapeutics Inc (XLO) in total and bought 485,250 shares, with a net purchase of 485,250 shares. During the past 18 months, 5,235 shares of Xilio Therapeutics Inc (XLO) were sold and 485,250 shares were bought by its insiders, resulting in a net purchase of 480,015 shares.
Xilio Therapeutics Inc (XLO)'s detailed insider trading history can be found in Insider Trading Tracker table.
Xilio Therapeutics Inc Insider Transactions
Bain Capital Life Sciences Fund Ii, L.p. Mailing Address
Above is the net worth, insider trading, and ownership report for Bain Capital Life Sciences Fund Ii, L.p.. You might contact Bain Capital Life Sciences Fund Ii, L.p. via mailing address: 200 Clarendon Street, Boston Ma 02116.
Discussions on Bain Capital Life Sciences Fund Ii, L.p.
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
